MedTrace Logo

Tailored Therapy for Helicobacter Pylori Rescue Treatment

NCT03413020 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-08-07

No results posted yet for this study

Summary

With increasing antibiotic resistance and unsatisfactory results of empiric eradication regimens, tailored therapy may be the best choice to achieve high efficacy for rescue treatment. This study aimed to evaluate the eradication rates, safety, and compliance of antimicrobial susceptibility-based tailored therapy for rescue treatment in patients with Helicobacter pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

esomeprazole

proton pump inhibitor

DRUG

bismuth Potassium Citrate

gastric mucosal protective drug with anti-H. pylori effect

DRUG

amoxicillin

antibiotic for H. pylori eradication

DRUG

clarithromycin

antibiotic for H. pylori eradication

DRUG

metronidazole

antibiotic for H. pylori eradication

DRUG

levofloxacin

antibiotic for H. pylori eradication

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Hong Lu, M.D. · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-03
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413020 on ClinicalTrials.gov